Find-Health-Articles.com - making medical research available to everyone
Research article summary (published 13 Apr 1989):

[Use of mifepristone in the termination of early pregnancy. The experience in France]

(Utilisation de la mifépristone dans l'interruption volontaire de grossesse. Expérience française.)

Full Abstract

Are reported the results obtained with mifepristone, administered alone or followed by a low dose of prostaglandin derivative, as an alternative to endometrial aspiration for termination of early pregnancy. Mifepristone was first used alone in doses of 600 mg in 1,841 women. Subsequently, 703 other women received, 36 to 48 hours after mifepristone, either sulprostone (a prostaglandin E2 analogue) 0.25 mg intramuscularly, or gemeprost (a prostaglandin E1 analogue) 1 mg as pessary, or meteneprost (a prostaglandin E2 analogue) 10 mg as pessary. Mifepristone administered alone was successful in 80 per cent of pregnant women with less than 42 days of amenorrhoea. The mifepristone-prostaglandin combination was successful in more than 95 per cent of pregnant women with less than 50 days of amenorrhoea. Expulsion of the ovum was difficult to date when mifepristone was used alone; it occurred within 24 hours of prostaglandin dosing in more than 80 per cent of the other women. Uterine bleeding was almost constant. It was more copious than the usual menses in the majority of women, with or without prostaglandin, and it sometimes required aspiration or curettage (mifepristone alone 1.3 per cent, with prostaglandin 0.28 per cent) and/or blood transfusion (mifepristone alone 0.4 per cent, with prostaglandin 0.14 per cent). Administered alone, mifepristone was very well tolerated. When prostaglandin analogues were added the women complained of lower abdominal pain which required a minor antalgic treatment in 30 to 50 per cent of the cases. Gastrointestinal side-effects were mild, probably due to the low doses of prostaglandin administered.

 

Author information

Author/s: Dubois, C (C); Silvestre, L (L); Ulmann, A (A);

Affiliation: Laboratoires Roussel, Paris.

Journal and publication information

Publication Type: English Abstract; Journal Article

Journal: Presse médicale (Paris, France : 1983) (Presse Med), published in FRANCE. (Language: fre)

Reference: 1989-Apr; vol 18 (issue 15) : pp 757-60

Dates: Created 1989/06/13; Completed 1989/06/13; Revised 2006/11/15;

PMID: 2524050, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Associated Chemicals: Abortifacient Agents (0) ; Abortifacient Agents, Steroidal (0) ; Estrenes (0) ; Prostaglandins (0) ; Mifepristone (84371-65-3)

Related articles

These are the highest related articles currently in the database:

See 100+ related articles.

Related Article Map

5/15/1982
6/29/2002
Higher Relevance Score (18)
Lower Relevance Score (13)

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.

© Advanogy LLC 2003-2009 - All rights reserved. Terms of Use | Contact Us | Index